C2i Genomics
C2i Genomics's Overview
C2i Genomics is a biotechnology company dedicated to transforming cancer care through ultra-sensitive treatment monitoring and disease intelligence. They leverage AI and whole-genome sequencing to provide minimal residual disease (MRD) detection and tumor evolution insights. Their platform, C2inform, aims to enable earlier detection of cancer recurrence, optimize treatment decisions, and ultimately improve patient outcomes by providing personalized, real-time data to oncologists.
Where is C2i Genomics's Headquarters?
HQ Function
The New York headquarters serves as the central hub for global operations, business development, commercial strategy, investor relations, and corporate governance.
Notable Features:
Located in the iconic 7 World Trade Center, offering a state-of-the-art facility in a prime business district with advanced infrastructure and connectivity.
Work Culture:
The work culture is likely dynamic, innovative, and mission-driven, fostering collaboration between scientific, technical, and business teams focused on advancing cancer care. There's an emphasis on cutting-edge research and translating it into impactful clinical solutions.
HQ Significance:
The NYC location places C2i Genomics at the heart of a major global financial, technological, and biopharmaceutical hub, facilitating access to talent, investment, and strategic partnerships.
Values Reflected in HQ: The choice of a prominent, forward-looking location reflects C2i Genomics' ambition, commitment to innovation, and focus on impactful, global solutions.
Location:
C2i Genomics operates with a global focus, with its primary corporate functions based in New York, USA, and its core R&D activities in Haifa, Israel. They collaborate with research institutions, pharmaceutical companies, and healthcare providers internationally to advance their cancer intelligence platform and make their MRD testing solutions accessible to patients worldwide. Their commercial activities are expanding into key markets in North America and Europe.
Street Address:
7 World Trade Center, 250 Greenwich St, Floor 46
City:
New York
State/Province:
NY
Country:
USA
C2i Genomics's Global Presence
Haifa, Israel
Address: MATAM Advanced Technology Park, Building 30, Haifa, Israel
Leverages Israel's renowned high-tech and biotech ecosystem, tapping into a rich talent pool for software engineering, artificial intelligence, and life sciences research to drive innovation in oncology.
Buying Intent Signals for C2i Genomics
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of C2i Genomics
As of April 2025, C2i Genomics' leadership includes:
Investors of C2i Genomics
C2i Genomics has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
In the past year, C2i Genomics has focused on strengthening its commercial and operational leadership. Notable appointments include a Chief Commercial Officer and a General Counsel. No high-profile executive departures have been publicly announced.
New Appointments:
Technology (Tech Stack) used by C2i Genomics
Discover the tools C2i Genomics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
C2i Genomics Email Formats and Examples
C2i Genomics likely utilizes common corporate email formats. While not publicly confirmed, standard patterns include [first_initial][last]@[companyname].com or [first].[last]@[companyname].com.
[first_initial][last]@c2i-genomics.com or [first].[last]@c2i-genomics.com
Format
jdoe@c2i-genomics.com or jane.doe@c2i-genomics.com
Example
80%
Success rate
News and media
Business Wire • October 24, 2023
C2i Genomics Presents New Data at ESMO 2023 Demonstrating High Sensitivity of Whole-Genome Sequencing MRD Assay for Monitoring Treatment Response in Multiple Cancer Types
C2i Genomics shared compelling new data at the European Society for Medical Oncology (ESMO) Congress 2023. The findings highlighted the C2inform MRD test's high sensitivity and specificity in detecting cancer recurrence and monitoring treatment response across various cancer types using whole-genome sequencing....more
GlobeNewswire • June 27, 2023
C2i Genomics Appoints Artur Kowalski as Chief Commercial Officer
C2i Genomics announced the appointment of Artur Kowalski as Chief Commercial Officer. Mr. Kowalski brings extensive experience in global diagnostics and genomics commercialization to drive the company's market expansion and adoption of its C2inform MRD test....more
PR Newswire • May 10, 2021
C2i Genomics Raises $100 Million Series B to Accelerate Development and Commercialization of AI-Powered Cancer Intelligence Platform
C2i Genomics secured $100 million in Series B funding led by Casdin Capital, with participation from NFX, Duquesne Family Office, Section 32, iGlobe Partners, and LionBird Ventures. The funding will be used to scale its AI-powered cancer intelligence platform for MRD detection and monitoring....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including C2i Genomics, are just a search away.